The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Official Title: A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Study ID: NCT02724254
Brief Summary: This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Anaconda Invesigational Site, Buenos Aires, , Argentina
Anaconda Investigational Site, Buenos Aires, , Argentina
Anaconda Investigational Site, Cordoba, , Argentina
Anaconda Investigational Site, Córdoba, , Argentina
Anaconda Investigational Site, Mendoza, , Argentina
Anaconda Investigational Site, Sante Fe, , Argentina
Anaconda Investigational Site, Concepción, , Chile
Anaconda Investigational Site, Santiago, , Chile
Anaconda Investigational Site, Cumbaya, , Ecuador
Anaconda Investigational Site, Guayaquil, , Ecuador
Anaconda Investigational Site, Quito, , Ecuador
Anaconda Investigational Site, Belgrade, , Serbia
Anaconda Investigational Site, Novi Sad, , Serbia
Name: Anna Novotney-Barry
Affiliation: Aviragen Therapeutics, Inc.
Role: STUDY_DIRECTOR